APAC Spatial Genomics and Transcriptomics Market Size, Share, Growth and Forecast, 2025-2035

Tissue maps move from atlas projects to drug research

The APAC spatial genomics and transcriptomics market was valued at USD 70.5 million in 2025 and is projected to increase from USD 90.0 million in 2026 to USD 403.9 million by 2035, registering a CAGR of 18.15% during 2026–2035. Demand comes from universities and public institutes that build tissue atlases, drug developers that study tumor and immune cells in place, and service laboratories that run instruments for groups without their own systems. Mainland China held the largest country share, 50.3% in 2025, because Stereo-seq was developed there and large atlas programs use it. South Korea is the fastest-growing country at 18.81% a year, as research spending stays high and service providers add new imaging platforms. Japan and the remaining markets add demand from drug research and national institutes. Panels have also grown from a few hundred genes to near whole transcriptome coverage since 2024, which widens the questions one tissue section can answer.

Which products and services does the regional estimate cover?

The estimate measures the value of instruments with bundled software, capture and preparation consumables, and detection and readout consumables sold to buyers in the Asia-Pacific region. It also counts the value of direct research service contracts in which a laboratory runs the assay for a customer. Values are measured at the first point of sale to the buying institute, company or hospital laboratory.

The estimate excludes general sequencers, standard microscopes and routine clinical pathology tests that do not record where molecules sit in tissue. The value chain runs from slide, probe and reagent makers through instrument owners, authorized distributors and service laboratories to universities, drug developers and hospital research groups across Mainland China, Japan, South Korea and the remaining markets of the region.

Sequencing chips lead while service labs grow fastest

Why do consumables outgrow instruments over time?

Based on product type, the market is categorized into instruments and bundled software, capture and preparation consumables, and detection and readout consumables. Instruments and Bundled Software led with a 38.0% share of 2025 value, because new imaging systems carry high unit prices. Detection and Readout Consumables grow fastest at 19.02% a year, as each installed system runs larger gene panels and more slides every year.

How does oncology research shape application demand?

Based on application, the market is categorized into oncology, neuroscience, developmental biology and immunology and cross-disease research. Oncology led with a 42.0% share of 2025 value, because tumor samples are the most common tissue that drug developers and hospitals profile. Immunology and Cross-Disease Research grows fastest at 18.58% a year, as immune atlases from Asian donors open new comparison studies.

Why do service laboratories gain share from institutes?

Based on end user, the market is categorized into academic and public research institutes, pharmaceutical and biotechnology companies, contract research and service laboratories, and hospital research laboratories. Academic and Public Research Institutes led with a 52.0% share of 2025 value, because atlas programs are publicly funded. Contract Research and Service Laboratories grow fastest at 19.36% a year, as more groups send slides out for analysis.

How do imaging platforms challenge sequencing chips?

Based on technology, the market is categorized into in situ imaging, spatial sequencing, digital spatial profiling and targeted and multimodal assays. Spatial Sequencing led with a 40.0% share of 2025 value, because it extends single-cell omics work onto tissue. Targeted and Multimodal Assays grow fastest at 18.96% a year, as RNA and protein are read on one slide.

Higher plex, atlas networks and service labs lift use

How does higher-plex detection widen research questions?

One tissue section can now show thousands of genes instead of a few dozen markers, which lets a single study test many cell types at once. 10x Genomics launched its Xenium Prime 5K panel on May 29, 2024, which raised plex about tenfold and covers up to 472 square millimeters of tissue in six days or less. Bruker then took advance orders in May 2025 for CosMx Whole Transcriptome, which covers about 19,000 gene targets, according to its AACR 2025 release. The same release said CosMx can pair the whole transcriptome with up to 76 immuno-oncology proteins in the same cell. As a result, detection and readout consumables grow at 19.02% a year, the fastest product rate in the region.

Why does research network expansion lift atlas demand?

Large consortia now map tissue across many laboratories and countries, and each member must buy matched chips, probes and reagents. Scientists from 16 countries formed the SpatioTemporal Omics Consortium in May 2022, with members such as the Genome Institute of Singapore, the University of Western Australia and BGI-Research. The Asian Immune Diversity Atlas profiled more than 1.2 million immune cells from 625 donors in five countries, according to A*STAR. Research funding also stays high, at 4.94% of GDP in South Korea and 3.44% in Japan in 2023, according to World Bank data. In turn, academic and public research institutes hold a 52.0% share of 2025 value.

Download Free Sample

How does service-based access lower the entry barrier?

Many groups need only a few studies a year, so buying results from a service laboratory costs less than owning a system. Macrogen introduced the 10x Genomics Atera platform in Asia on Sept. 9, 2026, and said it can process up to 800 whole transcriptome samples a year, according to Asia Economy. Macrogen already runs Xenium projects in about six weeks and CosMx projects in about five weeks. Omics Empower also began Xenium services at Hong Kong Science Park in February 2026, the second Hong Kong laboratory to run that system. As more drug developers use contract research outsourcing, service laboratories grow at 19.36% a year.

Why do grants and distributors speed first adoption?

Pilot funding and local sales partners cut the cost and risk of a first study for new laboratories. MGI Tech and STOmics opened a spatial grant program on Nov. 6, 2025, for Japan, South Korea and Southeast Asia, according to MGI Tech. Its awards include Stereo-seq pilot tests and large discounts on product kits. Vizgen signed distributors in October 2022 for China and Hong Kong, Japan, South Korea and Australia and New Zealand, while it sells directly in Singapore. These channels put local application scientists near new customers, which shortens training and sample checks. As a result, the remaining APAC markets hold a 33.0% share of 2025 value.

Same-slide multiomics and instrument-free kits gain ground

How is the shift to same-slide RNA and protein changing assays?

Researchers increasingly want cell identity and cell state from one tissue section, which pushes vendors to add protein readout to gene panels. 10x Genomics launched Xenium Protein on Aug. 19, 2025, which detects RNA and protein in the same cell in one automated run. Bio-Techne showed RNAscope with Lunaphore COMET on the same section in September 2025, using a 21-plex protein panel for lymphoid cancers. Bruker also planned CosMx same-slide multiomics for the second half of 2025. These tools bring multiplex biomarker imaging and gene panels into one workflow. As a result, targeted and multimodal assays grow at 18.96% a year, the fastest technology rate.

Why is the rise of instrument-free capture kits gaining weight?

Many laboratories in the region own sequencers but lack imaging systems, which makes kit-only tissue mapping attractive. Takara Bio USA, a subsidiary of Japan-based Takara Bio, bought Curio Bioscience on Jan. 14, 2025, adding the Seeker and Trekker technologies. In February 2026, it said Trekker with an Illumina single-cell kit recovers more than 100,000 spatially placed nuclei per sample without special hardware. 10x Genomics also launched Visium HD 3 prime gene expression on May 13, 2025, for human, mouse, rat, primate and zebrafish tissue. These kits use standard next-generation sequencing runs, so spatial sequencing keeps a 40.0% share of 2025 value.

Download Free Sample

Can Southeast Asia and Australia open new installed bases?

Institutes in Singapore, Thailand and Australia join regional atlas programs but hold far fewer systems than Mainland China. WEHI in Australia ran a MERSCOPE system when Vizgen signed its regional distributors in October 2022. Thailand and India supplied donors to the Asian Immune Diversity Atlas, alongside Singapore, South Korea and Japan. Research spending reached 1.86% of GDP in Australia in 2021 and 1.81% in Singapore in 2022, according to World Bank data. The STOmics grant also targets Southeast Asian groups with pilot tests and kit discounts. As a result, the remaining APAC markets grow at 18.31% a year, ahead of Mainland China.

Is there room for growth in drug developer tumor studies?

Tissue maps can show which immune cells reach a tumor and why some patients respond, which gives drug developers a reason to fund more studies. Macrogen aimed its Atera webinar in September 2026 at pharma and biotech staff, with topics such as tumor microenvironment analysis and immuno-oncology response prediction. Its CosMx service already offers a 100-plex RNA immuno-oncology panel and a 64-plex protein panel. Bruker's CosMx Whole Transcriptome assay, which reads about 19,000 gene targets, gives these studies a whole-tissue view. In turn, oncology holds a 42.0% share of 2025 value, and pharmaceutical and biotechnology companies are set to buy more studies from service laboratories.

Capital cost, data skills and sample quality slow uptake

How do high system prices limit smaller institutes?

Imaging platforms need capital budgets that many university departments cannot raise in one year. Universities outside the largest cities often share a single system across several groups. As a result, slides wait in queues and projects take longer to finish. Vendors respond with service partnerships, reagent rental plans and pilot grants, while institutes pool funds into core facilities that serve a whole campus.

Why do data volumes strain analysis skills?

A single whole transcriptome slide can produce hundreds of gigabytes of images and counts for each project. Many biology groups lack staff who can align cells, label cell types and test spatial patterns. In turn, raw data can sit unused for months after a run. Vendors respond with cloud analysis packages and AI cell segmentation, while institutes train bioinformatics staff and share pipelines across projects.

How does sample quality affect assay results?

RNA in archived tissue blocks breaks down with age, heat and poor storage conditions over many years. Hospitals in the region fix and store tissue in different ways, which makes results harder to compare across sites. As a result, studies may need repeat runs or extra quality checks before analysis. Service laboratories respond with strict sample rules on section thickness, block age and storage temperature.

Why does platform diversity slow data comparison?

Each commercial system uses its own panels, chemistry, resolution and file formats for results. A consortium that mixes imaging and sequencing methods must harmonize results before it can pool samples. In turn, multicountry atlas projects can take longer and cost more to complete. Consortia respond with shared reference tissues, common cell type labels and open data standards that let groups compare results across platforms.

Mainland China leads while South Korea grows fastest

Why does Mainland China hold half of regional value?

Mainland China held a 50.3% share of 2025 value and grows at 18.21% a year, because the country hosts the developer of Stereo-seq and the largest public atlas programs. Chinese teams used Stereo-seq to map 264 cell types across 143 regions of the macaque cortex in a study published in July 2023. China also spent 2.58% of GDP on research in 2023, which supports steady institute purchases of chips, reagents and sequencing.

How does Japan support drug research demand?

Japan held an 11.9% share of 2025 value and grows at 17.11% a year, because its drug companies and national institutes run long research programs that use tissue profiling. RIKEN took part in the Asian Immune Diversity Atlas, and Japan spent 3.44% of GDP on research in 2023. Takara Bio, based in Shiga, now owns the Trekker and Seeker technologies, while PRIMETECH distributes MERSCOPE systems in the country.

Download Free Sample

Why is South Korea the fastest-growing country?

South Korea held a 4.8% share of 2025 value and grows fastest at 18.81% a year, because it has the highest research spending in the region and an active service sector. The country spent 4.94% of GDP on research in 2023. Macrogen runs Visium, GeoMx, Xenium and CosMx services from Korea, and its Songdo Global Genome Center, completed in June 2026, is the base for the new Atera service.

What shapes demand in the remaining APAC markets?

The remaining APAC markets held a 33.0% share of 2025 value and grow at 18.31% a year. Singapore hosts the Genome Institute of Singapore, which led the Asian Immune Diversity Atlas, and Hong Kong now has at least two laboratories that run Xenium. Australia adds demand from medical research institutes such as WEHI, while Thailand and India join regional atlas work.

Download Free Sample

Acquisitions, panels and service launches, 2024 to 2026

Imaging, sequencing chips and same-slide protein readout

• In situ imaging reads RNA directly in tissue with cyclic probes, and panels now reach about 5,000 genes or near the whole transcriptome.
• Barcoded sequencing chips capture RNA on a slide with position codes, which lets labs read tissue maps on sequencers they already own.
• Digital spatial profiling measures RNA or protein in chosen tissue regions, which suits pathology studies on archived blocks.
• Same-slide multiomics adds protein panels to RNA readout in the same cell, which links cell identity to cell state.

Platform owners compete on plex, area and service reach

Competition combines global platform owners with a strong Chinese sequencing-based supplier and regional service laboratories. 10x Genomics sells Visium and Xenium systems and kits, and its platforms reach Korean buyers through Macrogen services. Bruker owns GeoMx and CosMx after its 2024 NanoString purchase, while STOmics sells Stereo-seq chips and runs grant programs across the region. Vizgen sells MERSCOPE through distributors in China, Japan, South Korea and Australia, and Takara Bio adds instrument-free Trekker kits. Bio-Techne competes in targeted RNA and protein imaging with RNAscope and COMET. Companies compete on plex, tissue area per run, turnaround and local support rather than on price alone. Service laboratories such as Macrogen and Omics Empower compete on turnaround, and Macrogen quotes about six weeks for Xenium projects and about five weeks for CosMx projects.

Which platform owners and service labs lead APAC?

Credence Research view on Asia-Pacific tissue profiling

Credence Research's view is that Asia-Pacific demand for tissue profiling will grow quickly because panels are larger, atlas networks are wider and service laboratories make studies easier to buy. Spatial sequencing remains the largest technology, while same-slide RNA and protein assays grow fastest. Mainland China keeps about half of regional value, and South Korea grows fastest among the named countries. However, system prices, data skills and sample quality will slow uptake in smaller institutes. Companies that pair high plex with local service and analysis support should gain share fastest.

How the regional tissue profiling estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines research spending statistics, atlas program data, product launch information and service capacity disclosed by companies. Segment splits, country shares and country growth rates are Credence Research estimates. Sources used are official statistics, research institute releases, company releases, news reports and company websites, and no interviews or surveys were used.

Translational research carries demand to 2035

The APAC spatial genomics and transcriptomics market is expected to reach USD 403.9 million by 2035, an 18.15% CAGR during 2026–2035, as larger panels and service access widen use. Growth should stay strong through 2028 while whole transcriptome imaging and same-slide protein assays spread to more laboratories. After that, consumables and service contracts will carry more growth as the installed base matures. Wider hospital research use would raise this outlook, while tighter research budgets would lower it. Companies with local service partners and strong analysis tools are expected to gain the most.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.